Company intelligence / Profile preview

InterMune

Brisbane, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~450
Development stage: Commercial

Overview

InterMune developed pirfenidone (Esbriet), a treatment for idiopathic pulmonary fibrosis. The drug received FDA approval in October 2014 after initially being rejected in 2010 and requiring additional Phase III trials. It was previously approved in Canada (2011) and Europe (2012).

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

amphotericin b cholesteryl sulfate complex

4 more assets in the full pipeline.

Request access →

Partnerships

Roche (2006-2010 collaboration before acquisition)

Beyond the preview

Go deeper on InterMune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterMune.

Explore the full profile